AI

Acadia Pharmaceuticals Inc.

www.acadia.com link_icon

Company Research Report: Acadia Pharmaceuticals Inc.



Company Overview



  • Name: Acadia Pharmaceuticals Inc.

  • Mission: Acadia is trailblazing breakthroughs in neuroscience to elevate life by developing innovative and novel medicines to help address unmet medical needs.

  • Founded: The company was founded in 1993 by Mark Brann, Ph.D., a professor at the University of Vermont.

  • Key People:

  • Catherine Owen Adams - Chief Executive Officer and Director

  • Jennifer J. Rhodes - Executive Vice President, Chief Legal Officer, and Secretary

  • Mark Schneyer - Executive Vice President, Chief Financial Officer

  • Brendan Teehan - Executive Vice President, Chief Operating Officer, Head of Commercial

  • Key members of the Board of Directors include Stephen Biggar, M.D., Ph.D. (Chairman) and several notable industry leaders.

  • Headquarters: San Diego, California, with major offices in Princeton, New Jersey.

  • Number of Employees: 500+

  • Revenue: In the third quarter of 2024, total revenues were reported at $250.4 million, projecting annualized sales exceeding $1 billion.

  • Known For: Acadia Pharmaceuticals is known for developing the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis and the first approved treatment for Rett syndrome in the U.S. and Canada.


Products



NUPLAZID® (pimavanserin)


  • High-level Description: NUPLAZID® is the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.

  • Key Features:

  • Targets 5-HT2A receptors, avoiding other receptor interactions.

  • Safety information includes warnings about increased mortality in elderly patients with dementia-related psychosis.

  • Significant adverse reactions noted include peripheral edema, nausea, and confusional state.


DAYBUE™ (trofinetide)


  • High-level Description: DAYBUE™ is the only FDA-approved treatment for Rett syndrome in adults and pediatric patients two years and older in the U.S. and Canada.

  • Key Features:

  • Synthetic version of the tripeptide glycine-proline-glutamate (GPE).

  • Common side effects include diarrhea, vomiting, and weight loss.

  • Adverse drug interactions noted when coadministered with CYP3A4 substrates.


Recent Developments


  • New Products Launched: Over 2023, DAYBUE™ was approved for the treatment of Rett syndrome in both the U.S. and Canada.

  • Recent Partnerships:

  • Strategic collaboration with Stoke Therapeutics to develop novel RNA-based medicines.

  • Partnership with Warren Center for Neuroscience Drug Discovery focused on muscarinic M1 receptor drug candidates.

  • Recent Business Activity:

  • Agreement to sell a Rare Pediatric Disease Priority Review Voucher for $150 million, with proceeds supporting commercial operations and R&D programs.

  • Leadership Changes: Catherine Owen Adams succeeded Steve Davis as CEO.

  • Financial Highlights:

  • Reporting a 3Q24 net income of $32.8 million, up from a loss in 2023.

  • The financial forecast for NUPLAZID and DAYBUE shows substantial sales growth.


Conclusion


With a robust pipeline aimed at addressing significant unmet needs in CNS disorders and considerable growth in FDA-approved products, Acadia Pharmaceuticals is positioned for continued innovation and expansion in the healthcare sector.

For additional details and future updates, visit Acadia's official channels or contact their media and investor relations teams.